Literature DB >> 21680793

Rates of treatment discontinuation due to adverse events for echinocandins.

Eckhard Müller, Jiun-Ling Wang, Chia-Hsuin Chang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21680793      PMCID： PMC3122447          DOI： 10.1128/AAC.00055-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Better reporting of harms in randomized trials: an extension of the CONSORT statement.

Authors:  John P A Ioannidis; Stephen J W Evans; Peter C Gøtzsche; Robert T O'Neill; Douglas G Altman; Kenneth Schulz; David Moher
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

2.  Reporting of safety results in published reports of randomized controlled trials.

Authors:  Isabelle Pitrou; Isabelle Boutron; Nizar Ahmad; Philippe Ravaud
Journal:  Arch Intern Med       Date:  2009-10-26

3.  Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.

Authors:  Jiun-Ling Wang; Chia-Hsuin Chang; Yinong Young-Xu; K Arnold Chan
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

4.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

Authors:  Ernst-Rüdiger Kuse; Ploenchan Chetchotisakd; Clovis Arns da Cunha; Markus Ruhnke; Carlos Barrios; Digumarti Raghunadharao; Jagdev Singh Sekhon; Antonio Freire; Venkatasubramanian Ramasubramanian; Ignace Demeyer; Marcio Nucci; Amorn Leelarasamee; Frédérique Jacobs; Johan Decruyenaere; Didier Pittet; Andrew J Ullmann; Luis Ostrosky-Zeichner; Olivier Lortholary; Sonja Koblinger; Heike Diekmann-Berndt; Oliver A Cornely
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

5.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

Authors:  Thomas J Walsh; Hedy Teppler; Gerald R Donowitz; Johan A Maertens; Lindsey R Baden; Anna Dmoszynska; Oliver A Cornely; Michael R Bourque; Robert J Lupinacci; Carole A Sable; Ben E dePauw
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

6.  Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Authors:  Peter G Pappas; Coleman M F Rotstein; Robert F Betts; Marcio Nucci; Deepak Talwar; Jan J De Waele; Jose A Vazquez; Bertrand F Dupont; David L Horn; Luis Ostrosky-Zeichner; Annette C Reboli; Byungse Suh; Raghunadharao Digumarti; Chunzhang Wu; Laura L Kovanda; Leah J Arnold; Donald N Buell
Journal:  Clin Infect Dis       Date:  2007-08-29       Impact factor: 9.079

7.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

8.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

9.  Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.

Authors:  David S Krause; John Reinhardt; Jose A Vazquez; Annette Reboli; Beth P Goldstein; Michele Wible; Timothy Henkel
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Comparison of echinocandin antifungals.

Authors:  Gregory Eschenauer; Daryl D Depestel; Peggy L Carver
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.